NNC 45-0095
![]() | |
临床资料 | |
---|---|
其他名称 | NNC-450095 |
药物类别 | 选择性雌激素受体调节物 |
识别信息 | |
| |
CAS号 | 217318-90-6 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C18H15NO |
摩尔质量 | 261.32 g·mol−1 |
3D模型(JSmol) | |
| |
|
NNC 45-0095是一种含氮有机化合物,化学式C18H17NO,可作为非甾体选择性雌激素受体调节物(SERMs),由诺和诺德开发,用于治疗骨质疏松症,从未上市销售。[1][2][3][4][5]
参考文献
- ^ Jørgensen AS, Jacobsen P, Christiansen LB, Bury PS, Kanstrup A, Thorpe SM, et al. Synthesis and pharmacology of a novel pyrrolo[2,1,5-cd] indolizine (NNC 45-0095), a high affinity non-steroidal agonist for the estrogen receptor. Bioorganic & Medicinal Chemistry Letters. February 2000, 10 (4): 399–402. PMID 10714509. doi:10.1016/S0960-894X(00)00015-9.
- ^ Sharma V, Kumar V. Indolizine: a biologically active moiety. Medicinal Chemistry Research. 2014, 23 (8): 3593–3606. ISSN 1054-2523. S2CID 2643469. doi:10.1007/s00044-014-0940-1.
- ^ Wallace OB, Richardson TI, Dodge JA. Estrogen receptor modulators: relationships of ligand structure, receptor affinity and functional activity. Current Topics in Medicinal Chemistry. 2003, 3 (14): 1663–1682. PMID 14683521. doi:10.2174/1568026033451727.
- ^ Meegan MJ, Lloyd DG. Understanding the Molecular Mechanism of Action of Estrogen Receptor Modulators. Frontiers in Medicinal Chemistry-Online. Atta-ur-Rahman, Reitz AB (编). Frontiers in Medicinal Chemistry 2. Bentham Science Publishers. January 2005: 183–231 (206). ISBN 978-1-60805-205-9.
|issue=
被忽略 (帮助) - ^ NNC 450095. AdisInsight. Springer Nature Switzerland AG. [2024-01-18]. (原始内容存档于2024-01-18).